Medscape4d
‘Take a Photograph’: Trial Shows Big Survival Gain in Advanced EGFR-Mutant NSCLC
PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...
Nasdaq5d
J&J : RYBREVANT + LAZCLUZE Outperforms Osimertinib In Phase 3 Trial For EGFR-Mutated Lung Cancer
Head-to-head comparison data versus osimertinib showed RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly extended OS in the first-line treatment of patients with locally ...
Yahoo Finance6d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice ...
Nasdaq11d
J&J Says Rybrevant, Lazcluze Combo Significantly Improved Survival In Lung Cancer Patients
(RTTNews) - Johnson & Johnson (JNJ) Thursday reported positive data from the Phase 3 MARIPOSA study evaluating rybrevant plus lazcluze versus osimertinib in the first-line treatment of patients ...
National Institute for Health and Care Excellence1mon
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...